Aaron M. Teitelbaum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aaron M. Teitelbaum has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Hamid Samareh Afsari
Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA
3 shared publications - Amit S. Kalgutkar
Medicine Design, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA
2 shared publications - Carley J. S. Heck
Medicine Design, Pfizer Worldwide Research, Development and Medical, Groton, CT, USA
2 shared publications - Mitchell E. Taub
Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA
2 shared publications - Steven Anderlot
Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA
2 shared publications - Ting Wang
Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA
2 shared publications
Latest Publications
- 7 April 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (15) , 11406-11415
Impact of High Mannose Glyco Pairing on the Pharmacokinetics of a Therapeutic monoclonal antibody using an Immunocapture-LC/MS Intact Assay
Many biotherapeutics, such as monoclonal antibodies (mAbs), consist of diverse glycoforms that can influence pharmacokinetic (PK) properties upon administration to animals and humans. Among these, N-glycosylation with high mannose (HM) at asparagin-297 is known to increase systemic clearance, shorten half-life, and reduce systemic exposure of mAbs. Therefore, the HM level is closely monitored and controlled within defined ranges during mAb production. However, the impact of glyco pairing (complex, asymmetrical HM and symmetrical HM) has not been previously investigated. Here, we present the first such study to assess the effects of HM glyco pairing on the PK of a therapeutic mAb. We developed a novel immunocapture-LC/MS intact analysis to distinguish and quantify different HM glyco pairings in rat plasma. The mAb was purified and enriched from the rat plasma using a biotinylated anti-human Fc Ab immobilized on streptavidin magnetic beads. Upon Endo-F3 enzymatic digestion, the purified samples yielded three N-glyco paired species: complex, asymmetrical HM and symmetrical HM, which were quantified, and their respective PK parameters were subsequently determined. There was a 2.4-fold and 4-fold increase in clearance for the asymmetrical HM and symmetrical HM compared to those of the complex, respectively. These in vivo findings were consistent with mannose receptor binding affinities of the glyco pair species. Our study underscores the importance of monitoring not only the high mannose levels but also the glyco pairing constructs during the mAb manufacturing process.
- 7 April 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (15) , 11406-11415
Impact of High Mannose Glyco Pairing on the Pharmacokinetics of a Therapeutic monoclonal antibody using an Immunocapture-LC/MS Intact Assay
Many biotherapeutics, such as monoclonal antibodies (mAbs), consist of diverse glycoforms that can influence pharmacokinetic (PK) properties upon administration to animals and humans. Among these, N-glycosylation with high mannose (HM) at asparagin-297 is known to increase systemic clearance, shorten half-life, and reduce systemic exposure of mAbs. Therefore, the HM level is closely monitored and controlled within defined ranges during mAb production. However, the impact of glyco pairing (complex, asymmetrical HM and symmetrical HM) has not been previously investigated. Here, we present the first such study to assess the effects of HM glyco pairing on the PK of a therapeutic mAb. We developed a novel immunocapture-LC/MS intact analysis to distinguish and quantify different HM glyco pairings in rat plasma. The mAb was purified and enriched from the rat plasma using a biotinylated anti-human Fc Ab immobilized on streptavidin magnetic beads. Upon Endo-F3 enzymatic digestion, the purified samples yielded three N-glyco paired species: complex, asymmetrical HM and symmetrical HM, which were quantified, and their respective PK parameters were subsequently determined. There was a 2.4-fold and 4-fold increase in clearance for the asymmetrical HM and symmetrical HM compared to those of the complex, respectively. These in vivo findings were consistent with mannose receptor binding affinities of the glyco pair species. Our study underscores the importance of monitoring not only the high mannose levels but also the glyco pairing constructs during the mAb manufacturing process.
- 8 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1
Correction: One-step Immobilization of Human α-1-acid Glycoprotein on Magnetic Beads: A Rapid Method for Small Molecule hAGP Binding Study
- 8 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1
Correction: One-step Immobilization of Human α-1-acid Glycoprotein on Magnetic Beads: A Rapid Method for Small Molecule hAGP Binding Study
- 18 September 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-12
One-step Immobilization of Human α-1-acid Glycoprotein on Magnetic Beads: A Rapid Method for Small Molecule hAGP Binding Study
Human α-1-acid glycoprotein (hAGP) immobilized directly on NHS ester (N-hydroxysuccinimide) activated magnetic beads (hAGP-beads) was developed as a n
- 18 September 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-12
One-step Immobilization of Human α-1-acid Glycoprotein on Magnetic Beads: A Rapid Method for Small Molecule hAGP Binding Study
Human α-1-acid glycoprotein (hAGP) immobilized directly on NHS ester (N-hydroxysuccinimide) activated magnetic beads (hAGP-beads) was developed as a n
- 2 July 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (7) , 1394-1408
Tailoring the Methods of Conjugation and Characterization for a Replication-Competent, Live, Viral Vector
Optimized functionalization of virus particles can expand the toolbox available for the development of viral vector-based therapies. However, labeling of a large, complex, and biologically active particle introduces distinct technological challenges for subsequent purification and characterization steps. Moreover, the process of labeling and purification, and even the label itself, may have an unwanted impact on the particle's biological activity. Herein, we present a comprehensive series of steps for conjugation, purification, and characterization that are adapted from traditional biologics (e.g., monoclonal antibodies) and apply them to the replication-competent rhabdovirus VSV-GP-GFP. By confirming purity and quantifying the average degree of labeling (DoL), we tailored the label/particle ratio to generate tool viruses suitable for downstream applications in nonclinical and clinical development. These methods will enhance the development of viral vector therapies and hasten their delivery to patients in need.
- 2 July 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (7) , 1394-1408
Tailoring the Methods of Conjugation and Characterization for a Replication-Competent, Live, Viral Vector
Optimized functionalization of virus particles can expand the toolbox available for the development of viral vector-based therapies. However, labeling of a large, complex, and biologically active particle introduces distinct technological challenges for subsequent purification and characterization steps. Moreover, the process of labeling and purification, and even the label itself, may have an unwanted impact on the particle's biological activity. Herein, we present a comprehensive series of steps for conjugation, purification, and characterization that are adapted from traditional biologics (e.g., monoclonal antibodies) and apply them to the replication-competent rhabdovirus VSV-GP-GFP. By confirming purity and quantifying the average degree of labeling (DoL), we tailored the label/particle ratio to generate tool viruses suitable for downstream applications in nonclinical and clinical development. These methods will enhance the development of viral vector therapies and hasten their delivery to patients in need.
- Open Access
- 20 February 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (3) , 296
Addressing the ADME Challenges of Compound Loss in a PDMS-Based Gut-on-Chip Microphysiological System
Microphysiological systems (MPSs) are promising in vitro technologies for physiologically relevant predictions of the human absorption, distribution, metabolism, and excretion (ADME) properties of drug candidates. However, polydimethylsiloxane (PDMS), a common material used in MPSs, can both adsorb and absorb small molecules, thereby compromising experimental results. This study aimed to evaluate the feasibility of using the PDMS-based Emulate gut-on-chip to determine the first-pass intestinal drug clearance. In cell-free PDMS organ-chips, we assessed the loss of 17 drugs, among which testosterone was selected as a model compound for further study based on its substantial ad- and absorptions to organ chips and its extensive first-pass intestinal metabolism with well-characterized metabolites. A gut-on-chip model consisting of epithelial Caco-2 cells and primary human umbilical vein endothelial cells (HUVECs) was established. The barrier integrity of the model was tested with reference compounds and inhibition of drug efflux. Concentration–time profiles of testosterone were measured in cell-free organ chips and in gut-on-chip models. A method to deduce the metabolic clearance was provided. Our results demonstrate that metabolic clearance can be determined with PDMS-based MPSs despite substantial compound loss to the chip. Overall, this study offers a practical protocol to experimentally assess ADME properties in PDMS-based MPSs.
- 20 February 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (3) , 296
Open AccessAddressing the ADME Challenges of Compound Loss in a PDMS-Based Gut-on-Chip Microphysiological System
Microphysiological systems (MPSs) are promising in vitro technologies for physiologically relevant predictions of the human absorption, distribution, metabolism, and excretion (ADME) properties of drug candidates. However, polydimethylsiloxane (PDMS), a common material used in MPSs, can both adsorb and absorb small molecules, thereby compromising experimental results. This study aimed to evaluate the feasibility of using the PDMS-based Emulate gut-on-chip to determine the first-pass intestinal drug clearance. In cell-free PDMS organ-chips, we assessed the loss of 17 drugs, among which testosterone was selected as a model compound for further study based on its substantial ad- and absorptions to organ chips and its extensive first-pass intestinal metabolism with well-characterized metabolites. A gut-on-chip model consisting of epithelial Caco-2 cells and primary human umbilical vein endothelial cells (HUVECs) was established. The barrier integrity of the model was tested with reference compounds and inhibition of drug efflux. Concentration–time profiles of testosterone were measured in cell-free organ chips and in gut-on-chip models. A method to deduce the metabolic clearance was provided. Our results demonstrate that metabolic clearance can be determined with PDMS-based MPSs despite substantial compound loss to the chip. Overall, this study offers a practical protocol to experimentally assess ADME properties in PDMS-based MPSs.
- Open Access
- 2 February 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (4) , 2832-2850
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science
Genome-wide association studies in patients revealed HSD17B13 as a potential new target for the treatment of nonalcoholic steatohepatitis (NASH) and other liver diseases. However, the physiological function and the disease-relevant substrate of HSD17B13 remain unknown. In addition, no suitable chemical probe for HSD17B13 has been published yet. Herein, we report the identification of the novel potent and selective HSD17B13 inhibitor BI-3231. Through high-throughput screening (HTS), using estradiol as substrate, compound 1 was identified and selected for subsequent optimization resulting in compound 45 (BI-3231). In addition to the characterization of compound 45 for its functional, physicochemical, and drug metabolism and pharmacokinetic (DMPK) properties, NAD+ dependency was investigated. To support Open Science, the chemical HSD17B13 probe BI-3231 will be available to the scientific community for free via the opnMe platform, and thus can help to elucidate the pharmacology of HSD17B13.
- 2 February 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (4) , 2832-2850
Open AccessDiscovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science
Genome-wide association studies in patients revealed HSD17B13 as a potential new target for the treatment of nonalcoholic steatohepatitis (NASH) and other liver diseases. However, the physiological function and the disease-relevant substrate of HSD17B13 remain unknown. In addition, no suitable chemical probe for HSD17B13 has been published yet. Herein, we report the identification of the novel potent and selective HSD17B13 inhibitor BI-3231. Through high-throughput screening (HTS), using estradiol as substrate, compound 1 was identified and selected for subsequent optimization resulting in compound 45 (BI-3231). In addition to the characterization of compound 45 for its functional, physicochemical, and drug metabolism and pharmacokinetic (DMPK) properties, NAD+ dependency was investigated. To support Open Science, the chemical HSD17B13 probe BI-3231 will be available to the scientific community for free via the opnMe platform, and thus can help to elucidate the pharmacology of HSD17B13.
- 1 March 2022
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 50 (3) , 258-267
Future of Biotransformation Science in the Pharmaceutical Industry
Over the past decades, the number of scientists trained in departments dedicated to traditional medicinal chemistry, biotransformation and/or chemical toxicology have seemingly declined. Yet, there remains a strong demand for such specialized skills in the pharmaceutical industry, particularly within drug metabolism/pharmacokinetics (DMPK) departments. In this position paper, the members of the Biotransformation, Mechanisms, and Pathways Focus Group (BMPFG) steering committee reflect on the diverse roles and responsibilities of scientists trained in the biotransformation field in pharmaceutical companies and contract research organizations. The BMPFG is affiliated with the International Society for the Study of Xenobiotics (ISSX) and was specifically created to promote the exchange of ideas pertaining to topics of current and future interest involving the metabolism of xenobiotics (including drugs). The authors also delve into the relevant education and diverse training skills required to successfully nurture the future cohort of industry biotransformation scientists and guide them towards a rewarding career path. The ability of scientists with a background in biotransformation/organic chemistry to creatively solve complex drug metabolism problems encountered during research and development efforts on both small molecule or large molecular modalities is exemplified in five relevant case studies. Finally, the authors stress the importance and continued commitment to training the next generation of biotransformation scientists who are not only experienced in the metabolism of conventional small molecule therapeutics, but are also equipped to tackle emerging challenges associated with new drug discovery modalities including peptides, protein degraders and antibodies. Significance Statement Biotransformation and mechanistic drug metabolism scientists are critical to advancing chemical entities through discovery and development, yet the number of scientists academically trained for this role is on the decline. This position paper highlights the continuing demand for biotransformation scientists and the necessity to nurture creative ways to train them and guarantee the future growth of this field.
- 1 March 2022
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 50 (3) , 258-267
Future of Biotransformation Science in the Pharmaceutical Industry
Over the past decades, the number of scientists trained in departments dedicated to traditional medicinal chemistry, biotransformation and/or chemical toxicology have seemingly declined. Yet, there remains a strong demand for such specialized skills in the pharmaceutical industry, particularly within drug metabolism/pharmacokinetics (DMPK) departments. In this position paper, the members of the Biotransformation, Mechanisms, and Pathways Focus Group (BMPFG) steering committee reflect on the diverse roles and responsibilities of scientists trained in the biotransformation field in pharmaceutical companies and contract research organizations. The BMPFG is affiliated with the International Society for the Study of Xenobiotics (ISSX) and was specifically created to promote the exchange of ideas pertaining to topics of current and future interest involving the metabolism of xenobiotics (including drugs). The authors also delve into the relevant education and diverse training skills required to successfully nurture the future cohort of industry biotransformation scientists and guide them towards a rewarding career path. The ability of scientists with a background in biotransformation/organic chemistry to creatively solve complex drug metabolism problems encountered during research and development efforts on both small molecule or large molecular modalities is exemplified in five relevant case studies. Finally, the authors stress the importance and continued commitment to training the next generation of biotransformation scientists who are not only experienced in the metabolism of conventional small molecule therapeutics, but are also equipped to tackle emerging challenges associated with new drug discovery modalities including peptides, protein degraders and antibodies. Significance Statement Biotransformation and mechanistic drug metabolism scientists are critical to advancing chemical entities through discovery and development, yet the number of scientists academically trained for this role is on the decline. This position paper highlights the continuing demand for biotransformation scientists and the necessity to nurture creative ways to train them and guarantee the future growth of this field.
- Open Access
- 24 June 2021
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 53 (3) , 384-433
Novel advances in biotransformation and bioactivation research – 2020 year in review
This annual review is the sixth of its kind since 2016 (see references). Our objective is to explore and share articles which we deem influential and significant in the field of biotransformation and bioactivation. These fields are constantly evolving with new molecular structures and discoveries of corresponding pathways for metabolism that impact relevant drug development with respect to efficacy and safety. Based on the selected articles, we created three sections: (1) drug design, (2) metabolites and drug metabolizing enzymes, and (3) bioactivation and safety (Table 1). Unlike in years past, more biotransformation experts have joined and contributed to this effort while striving to maintain a balance of authors from academic and industry settings.
- 24 June 2021
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 53 (3) , 384-433
Open AccessNovel advances in biotransformation and bioactivation research – 2020 year in review
This annual review is the sixth of its kind since 2016 (see references). Our objective is to explore and share articles which we deem influential and significant in the field of biotransformation and bioactivation. These fields are constantly evolving with new molecular structures and discoveries of corresponding pathways for metabolism that impact relevant drug development with respect to efficacy and safety. Based on the selected articles, we created three sections: (1) drug design, (2) metabolites and drug metabolizing enzymes, and (3) bioactivation and safety (Table 1). Unlike in years past, more biotransformation experts have joined and contributed to this effort while striving to maintain a balance of authors from academic and industry settings.
- 1 February 2019
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 368 (2) , 308-316
Influence of Stereochemistry on the Bioactivation and Glucuronidation of 4-Ipomeanol
A potential CYP4B1 suicide gene application in engineered T-cell treatment of blood cancers has revived interest in the use of 4-Ipomeanol (IPO) in gene-directed enzyme prodrug therapy, where disposition of the administered compound may be critical. IPO contains one chiral center at the carbon bearing a secondary alcohol group; it was of interest to determine the effect of stereochemistry on (i) CYP4B1-mediated bioactivation and (ii) UGT-mediated glucuronidation. (R)-IPO and (S)-IPO were synthesized and utilized, firstly, to assess cytotoxicity in HepG2 cells expressing rabbit CYP4B1 and re-engineered human CYP4B1, where the enantiomers were found to be equipotent. Next, a sensitive UPLC-MS/MS assay was developed to measure the IPO glucuronide diastereomers and product stereoselectivity in human tissue microsomes. Human liver and kidney microsomes generated (R)- and (S)-IPO-glucuronide diastereomers in ratios of 57:43 and 79:21, respectively. In a panel of thirteen recombinantly expressed UGTs, UGT1A9 and UGT2B7 were the major isoforms responsible for IPO glucuronidation. (R)-IPO-glucuronide diastereoselectivity was apparent with each rUGT, except UGT2B15 and UGT2B17, which favored the formation of (S)-IPO-glucuronide. Incubations with IPO and the UGT1A9 specific chemical inhibitor niflumic acid significantly decreased glucuronidation in human kidney, but only marginally in human liver microsomes, consistent with known tissue expression patterns of UGTs. We conclude that IPO glucuronidation in human kidney is mediated by UGT1A9 and UGT2B7, and in human liver, primarily by UGT2B7 and to a lesser extent UGT1A9 and UGT2B15. Overall, the lack of pronounced stereoselectivity for IPO9s bioactivation in CYP4B1-transfected HepG2 cells, or for hepatic glucuronidation, suggests the racemate is an appropriate choice for use in suicide gene therapies.
- 1 February 2019
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 368 (2) , 308-316
Influence of Stereochemistry on the Bioactivation and Glucuronidation of 4-Ipomeanol
A potential CYP4B1 suicide gene application in engineered T-cell treatment of blood cancers has revived interest in the use of 4-Ipomeanol (IPO) in gene-directed enzyme prodrug therapy, where disposition of the administered compound may be critical. IPO contains one chiral center at the carbon bearing a secondary alcohol group; it was of interest to determine the effect of stereochemistry on (i) CYP4B1-mediated bioactivation and (ii) UGT-mediated glucuronidation. (R)-IPO and (S)-IPO were synthesized and utilized, firstly, to assess cytotoxicity in HepG2 cells expressing rabbit CYP4B1 and re-engineered human CYP4B1, where the enantiomers were found to be equipotent. Next, a sensitive UPLC-MS/MS assay was developed to measure the IPO glucuronide diastereomers and product stereoselectivity in human tissue microsomes. Human liver and kidney microsomes generated (R)- and (S)-IPO-glucuronide diastereomers in ratios of 57:43 and 79:21, respectively. In a panel of thirteen recombinantly expressed UGTs, UGT1A9 and UGT2B7 were the major isoforms responsible for IPO glucuronidation. (R)-IPO-glucuronide diastereoselectivity was apparent with each rUGT, except UGT2B15 and UGT2B17, which favored the formation of (S)-IPO-glucuronide. Incubations with IPO and the UGT1A9 specific chemical inhibitor niflumic acid significantly decreased glucuronidation in human kidney, but only marginally in human liver microsomes, consistent with known tissue expression patterns of UGTs. We conclude that IPO glucuronidation in human kidney is mediated by UGT1A9 and UGT2B7, and in human liver, primarily by UGT2B7 and to a lesser extent UGT1A9 and UGT2B15. Overall, the lack of pronounced stereoselectivity for IPO9s bioactivation in CYP4B1-transfected HepG2 cells, or for hepatic glucuronidation, suggests the racemate is an appropriate choice for use in suicide gene therapies.
- 1 October 2007
- Published by Elsevier in Contraception
- Vol. 76 (4) , 335
Erratum to “Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials” [Contraception 76 (2007) 53–56]
- 1 October 2007
- Published by Elsevier in Contraception
- Vol. 76 (4) , 335
Erratum to “Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials” [Contraception 76 (2007) 53–56]